UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2013
Commission File Number
Novogen Limited
(Translation of registrants name into English)
1-7 Waterloo Road, Macquarie Park, NSW, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ¨ No x
If yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Novogen Limited (Registrant) |
Andrew Bursill |
Andrew Bursill |
Company Secretary |
Date 7 May 2013 |
7 May 2013
ASX RELEASE
Novogen Announces New Executive Appointments
Novogen today announces two new executive appointments as part of its recent acceleration of its R&D programs and to support an expansion of the Companys activities into North America.
Dr David Brown has been appointed Chief Scientific Officer. David is a biologist who between 2000 and 2010 was responsible for the pre-clinical testing of Novogen oncology drugs including Phenoxodiol, Triphendiol, NV128, NV-143 and NV-344. In 2010, David left Novogen and joined Janssen as a Medical Advisor. He now returns to head up the Novogen R&D program. David will be based in Sydney. His role will be to oversee the pre-clinical development of the Companys drugs pipeline of CS-6 and two recently-identified lead drug candidates with a focus on melanoma and pancreatic cancer.
Dr Andrew Heaton has been appointed President and CEO of the Companys newly-established North American subsidiary, Novogen North America Inc. This wholly-owned subsidiary has been established to service the rapidly-expanding R&D and corporate activities of the Company in the US and Europe. Andrew will continue to oversee the Companys drug discovery program and the manufacture of drug ahead of clinical testing, both activities now centered in Europe. The Company is based in New York City and will provide a means to better interact with the Companys US-based shareholders who currently represent approximately 70% of the Companys share base, as well as the FDA and the SEC.
About Novogen
Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol NRT) and NASDAQ (symbol NVGN). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells. The Companys inaugural drug candidate is CS-6.
About CS-6
CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitor cells, cancer stem cells. CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer cells and ovarian cancer stem cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer.
Further information
Contact Dr Graham Kelly, Chief Executive Officer.
M: (61) 0459 200 095
E: Graham.Kelly@novogen.com
Please note that the Company currently is relocating offices and that the original phone numbers no longer are in use. New contact details will be available shortly.
Further information is available on the Companys web site, www.novogen.com